Medcap Ab · OMXSTO:MCAP
Medcap Ab — Shareholder Meeting (May 2025)
13 slides from Medcap Ab's shareholder meeting presentation, May 5, 2025
Slide 1: Annual General Meeting May 5, 2025
Annual General Meeting May 5, 2025
Slide 2: We create value in Life Science and contribute to improved quality of life
We create value in Life Science and contribute to improved quality of life 2
Slide 3: MedCap Snapshot
MedCap Snapshot [2025 first quarter] Revenue, Business Areas Strategy LTM million SEK Assistive MedTech Specialty Buy & Build Tech Pharma 1 839 A long-term home for well run Life Science companies EBITA margin Q1-25 Employees & locations EBITA CAGR 5 years 17% 607 23% 3
Slide 4: Sales and EBITA development
Sales and EBITA development • Revenue increased by 14%, of which 6% organic • Adj EBITA margin at 17% • Specialty pharma’s result dropped by more than 50% due to changed market conditions in the UK • Strong development in Assistive Tech and MedTech, with EBITA growth of 35% and 19%, respectively 4
Slide 5: MedCap | An active investor in Life Science companies
MedCap | An active investor in Life Science companies Last Twelve Months, Q4 2024 Sales by Business Area Sales by Market RoW 4% Specialty Pharma Europe 24% 21% Assistive Tech 1 807 42% Sweden MSEK 50% Nordic MedTech 25% 34% 5
Slide 6: Our Model
Our Model Life Science Entrepreneurship Group Scale Sector focus Decentralized & local responsibility Scalable business areas Network of expertise Integrity of acquired brands Merger & Acquisitions Knowledge sharing Quick & agile, yet long-term mindset Governance – ESG Market insight Ambitious organ
Slide 7: Success factors
Success factors Solid markets Understanding the eco-systems Active ownership Non-cyclical Payor Prescriber End-user People & Management Demographic drivers Healthcare providers Distribution Business objectives Market nisches Regulation Sales & Marketing Performance management Market share potential
Slide 8: MedCap Business Areas
MedCap Business Areas Assistive Tech Med Tech Specialty Pharma Cognition, Alarms, Accessibility Diagnostic ECG Probiotics, Nutrition, Pharma CDMO Communication Packaging Digitalizing work-flow Contract manufacturing Nordic Sales, Pharma Sterile & non-sterile portfolio, Non-license liquid pharma prod
Slide 9: Highlights 2024
Highlights 2024 1 5 Abilias kognitionsprodukter växer Inpac flyttar verksamheten till vidare på den norska och svenska ny modernproduktions- marknaden och steg tas för att nå anläggning med bibehållen fler geografier leverans till kunderna 2 6 Affärsområdet Hjälpmedel och Konkurrensen ökar på den Ab
Slide 10: Investment strategy
Investment strategy Scope What we look for Life Science Assistive | MedTech | Pharma Product / Software / Know-how Value creation journey Europe Clear value proposition Scalable business Add-ons globally M&A possibilities Market fundamentals ESG Innovative PEOPLE Small / Mid-size Businesses Entrepre
Slide 11: Financial Targets
Financial Targets Annual EBITA Growth Return on Equity Net debt / EBITDA Compounded Average Growth Rate [MSEK] >15% >20% <3x 400 3 350 25% 2.5 300 20% 2 250 1.5 15% 200 1 10% 150 0.5 100 5% 0 50 0% 2019 2020 2021 2022 2023 2024 -0.5 0 2019 2020 2021 2022 2023 2024 -1 11
Slide 12: Why MedCap?
Why MedCap? 1 2 3 4 Sustainable Industry Profitable Growth Proven & Scalable Model Large & Growing Market Life Science industry Annual growth of 19% over Decentralized model – Fragmented market – many improves quality of life the last 5 years customer focused small and medium sized life responsibili
Slide 13: Group Highlights Q1
Group Highlights Q1 • Sales growth 7%; organic 0% (6% organic growth excl. Specialty Pharma Q1 2025 with high comparison figures) Net Sales • Good sales in Assistive Tech and MedTech; (MSEK) 493.8 +7% Specialty Pharma weaker as expected • EBITA decreased by 5% excluding Adj EBITA acquisition related